Back

XORTX targets Q4 2026 FDA filing for XRx-026 gout drug

Verifying
  • XORTX plans to submit an IND for its XRx-026 gout program to the FDA.
  • US$700 million is XORTX’s estimated annual market opportunity for XRx-026.
  • XORTX targets an NDA submission approximately one year after completing XRX-OXY-102, subject to funding.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.